Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research note released on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

LXRX has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. Piper Sandler lowered their price objective on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. Leerink Partnrs lowered shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $1.00 price objective (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Lexicon Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $3.67.

Lexicon Pharmaceuticals Trading Up 64.1 %

Shares of LXRX opened at $0.57 on Friday. Lexicon Pharmaceuticals has a twelve month low of $0.28 and a twelve month high of $2.45. The firm has a market capitalization of $140.48 million, a P/E ratio of -0.76 and a beta of 1.04. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. The stock’s fifty day simple moving average is $0.61 and its 200 day simple moving average is $1.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The business had revenue of $26.55 million during the quarter, compared to analysts’ expectations of $6.48 million. On average, equities research analysts forecast that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current year.

Institutional Trading of Lexicon Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Bayesian Capital Management LP acquired a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at $31,000. RPO LLC acquired a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $33,000. Renaissance Technologies LLC bought a new position in shares of Lexicon Pharmaceuticals during the fourth quarter worth about $38,000. Arizona State Retirement System grew its stake in Lexicon Pharmaceuticals by 34.4% in the fourth quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 16,136 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its holdings in Lexicon Pharmaceuticals by 60.3% in the fourth quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 24,615 shares during the last quarter. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.